Medifast Announces Third Quarter 2025 Financial Results November 3, 2025 BALTIMORE – (BUSINESS WIRE) — Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the third quarter ended September 30, 2025. Third Quarter 2025 "We're transforming Medifast from a weight-loss company into a leader in promoting metabolic health," said Dan Chard, Chairman and Chief Executive Officer of Medifast. "Our clinically proven, coach-guided ...

SAFETY INSURANCE GROUP, INC. ANNOUNCES THIRD QUARTER 2025 RESULTS AND DECLARES FOURTH QUARTER 2025 DIVIDEND Boston, Massachusetts, November 3, 2025. Safety Insurance Group, Inc. (NASDAQ:SAFT) ("Safety" or the "Company") today reported third quarter 2025 results. George M. Murphy, Chairman of the Board of Directors, President and Chief Executive Officer, commented: "For the quarter ended September 30, 2025, our combined ratio improved to 98.9% compared to 100.7% in the same period in the prior year. The year ...

Table of Contents As filed with the Securities and Exchange Commission on November 3, 2025 IAC Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from__________t ...

Financial Performance - Revenue for Q3 2025 was $310.7 million, an increase of 34.2% year-over-year, driven by a higher number of billers and increased transactions[1][8] - Adjusted EBITDA rose to $35.9 million, a 45.9% year-over-year increase, resulting in a 36.5% adjusted EBITDA margin[1][8] - Contribution profit for the quarter was $98.3 million, reflecting a year-over-year increase of 22.8%[1][8] - Non-GAAP net income was $22.6 million, compared to $14.7 million in the prior period, with diluted non-GAAP earnings per share at $0.17, up from $0.12[1][8] - Net income for the quarter was $17.7 million, compared to $14.4 million in the prior period, with diluted GAAP earnings per share at $0.14[1][8] - Revenue for Q3 2025 reached $310,737,000, a 34% increase from $231,571,000 in Q3 2024[29] - Gross profit for Q3 2025 was $74,849,000, up 23% from $60,665,000 in Q3 2024[29] - Adjusted EBITDA for Q3 2025 was $35,852,000, with an adjusted EBITDA margin of 36.5%, compared to 30.7% in Q3 2024[37] - Contribution profit for Q3 2025 was $98,266,000, up from $80,004,000 in Q3 2024, reflecting a 23% increase[36] - Non-GAAP net income for Q3 2025 was $22,572,000, compared to $14,717,000 in Q3 2024, reflecting a 53.5% year-over-year growth[40] - The company’s income before taxes under GAAP for Q3 2025 was $22,602,000, up from $14,435,000 in Q3 2024, a growth of 56.5%[40] Operational Metrics - The company processed 182.3 million transactions in Q3 2025, up 17.4% from the same quarter in 2024[1][8] - Cash and cash equivalents at the end of Q3 2025 totaled $287,908,000, an increase from $205,900,000 at the end of Q4 2024[31] - Total assets as of September 30, 2025, were $644,412,000, up from $576,247,000 at the end of 2024[31] - Total stockholders' equity increased to $537,402,000 as of September 30, 2025, compared to $485,596,000 at the end of 2024[31] - Operating cash flow for the nine months ended September 30, 2025, was $116,996,000, significantly higher than $35,721,000 for the same period in 2024[32] - The company reported net cash provided by operating activities of $35,076,000 in Q3 2025, compared to $6,737,000 in Q3 2024, marking a substantial increase[41] Guidance and Future Outlook - For Q4 2025, the company expects revenue between $307 million and $312 million, and for the full fiscal year 2025, revenue guidance is set at $1,173 million to $1,178 million[1][7] - Strong bookings year-to-date and a considerable backlog provide visibility for the remainder of 2025 and into 2026[2] Expenses and Investments - Research and development expenses for Q3 2025 were $15,219,000, a 15% increase from $13,187,000 in Q3 2024[29] - GAAP operating expenses for Q3 2025 were $54,988,000, up from $48,577,000 in Q3 2024, representing a 9.2% increase[39] - Non-GAAP operating expenses for the nine months ended September 30, 2025, were $142,706,000, up from $128,658,000 in the same period of 2024, a rise of 10.9%[39] - Stock-based compensation for Q3 2025 was $5,724,000, compared to $3,168,000 in Q3 2024, reflecting an increase of 80.4%[40] - Capitalized internal-use software development costs for Q3 2025 were $9,248,000, slightly higher than $8,876,000 in Q3 2024[41] Shareholder Information - The weighted-average shares of common stock diluted increased to 129,249,477 in Q3 2025 from 127,614,115 in Q3 2024[40] - Free cash flow for Q3 2025 was $25,725,000, a significant improvement from a negative free cash flow of $(2,211,000) in Q3 2024[41]

Exhibit 99.1 Announced launch of AdvanceAD-Tx™, the Company's test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD) Q3 2025 total test reports for our core revenue drivers (DecisionDx -Melanoma, TissueCypher ) increased 36% over Q3 2024 ® ® Castle Biosciences Reports Third Quarter 2025 Results Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Conference call and webcast toda ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 28, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14543 ____________________________________ TrueBlue, Inc. (Exact name of registrant as specified in its charter) ______________________________________ Washington 91-1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 01-0393723 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) (Address of principal executive offices) (ZIP Code) One IDEXX Drive Westbrook M ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-39590 FuboTV Inc. (Exact Name of Registrant as Specified in Its Charter) | Dela ...

Regulatory Approvals - In September 2025, argenx received approval in Japan for VYVDURA prefilled syringe for self-injection for treating adult patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy [152]. - In July 2025, Janssen announced European Commission approval for a new indication for DARZALEX SC as a monotherapy for high-risk adult patients with smoldering multiple myeloma [152]. - In June 2023, argenx received FDA approval for VYVGART Hytrulo for generalized myasthenia gravis, followed by European Commission approval in November 2023 and Japan approval in January 2024 [178]. - In July 2023, argenx reported positive data from the ADHERE study for VYVGART Hytrulo in chronic inflammatory demyelinating polyneuropathy, with FDA approval announced in June 2024 [178]. - OCREVUS SC received EU marketing authorization in June 2024 for a ten-minute injection, administered twice a year for multiple sclerosis [164]. - Takeda's HYQVIA received FDA approval for treating Primary Immunodeficiency in children in April 2023, expanding its use [169]. - BMS's Opdivo Qvantig, the first SC programmed death 1 inhibitor, received FDA approval in December 2024 for multiple adult solid tumors [176]. - Roche's TECENTRIQ SC was approved by the FDA in September 2024, further enhancing its market presence [163]. Collaborations and Acquisitions - Halozyme agreed to acquire Elektrofi, Inc. for $750 million upfront and up to three $50 million milestone payments contingent on product regulatory approvals, expected to close in Q4 2025 [152]. - The company licenses its ENHANZE technology to major biopharmaceutical companies, enhancing the delivery of high-dose injectable biologics [148]. - Halozyme's collaborations include partnerships with Roche, Takeda, Pfizer, Janssen, AbbVie, Lilly, BMS, argenx, ViiV, Chugai, and Acumen [149]. - In November 2023, argenx entered into a collaboration with Acumen to explore the use of ENHANZE for ACU193, targeting early Alzheimer's disease [185]. - In March 2025, ViiV announced that N6LS administered every four months with ENHANZE successfully maintained viral suppression in adults living with HIV [182]. Product Development and Technology - Halozyme has commercialized auto-injector products with Teva and Otter, and has development programs with McDermott Laboratories Limited [150]. - Halozyme's proprietary product portfolio includes Hylenex and XYOSTED, utilizing rHuPH20 and auto-injector technology respectively [150]. - ENHANZE technology may reduce patient treatment burden by enabling shorter administration times compared to intravenous methods [148]. - ATRS-1902 is a proprietary drug-device combination product for adrenal crisis rescue, with a Phase 1 clinical study initiated in September 2021 [158]. - Positive results from the Phase 1 study of ATRS-1902 led to Fast Track designation by the FDA, advancing the program to a pivotal study [159]. - The FDA accepted the IND application for ATRS-1902, allowing the initiation of clinical studies to compare its pharmacokinetics with Solu-Cortef [158]. - The company is actively expanding its product portfolio through collaborations and new product candidates in the pipeline [154]. Financial Performance - Royalties for the three months ended September 30, 2025, were $236,038, a 52% increase from $155,061 in 2024, driven by sales of ENHANZE partner products [192]. - Proprietary product sales for the three months ended September 30, 2025, were $52,242, a 31% increase from $39,925 in 2024, primarily due to market penetration of XYOSTED [192]. - Total product sales, net for the three months ended September 30, 2025, were $94,228, a 9% increase from $86,659 in 2024 [192]. - Revenues under collaborative agreements for the three months ended September 30, 2025, were $23,998, a 50% decrease from $48,364 in 2024, primarily due to timing of milestones achieved [194]. - Royalties for the nine months ended September 30, 2025, increased by 52% to $609,869,000 compared to $400,572,000 in 2024, driven by sales of ENHANZE partner products [202]. - Total product sales, net for the nine months ended September 30, 2025, increased by 13% to $253,779,000 from $224,128,000, primarily due to increased sales of proprietary product XYOSTED [203]. - Revenues under collaborative agreements decreased by 12% to $81,196,000 from $92,616,000, primarily due to the timing of milestones achieved [204]. Operating Expenses and Cash Flow - Operating expenses for the three months ended September 30, 2025, increased by 12% in cost of sales to $55,242,000 compared to $49,426,000 in 2024 [195]. - Research and development expenses decreased by 7% to $17,251,000 from $18,458,000, primarily due to lower compensation expenses [197]. - Selling, general and administrative expenses rose by 12% to $46,088,000, driven by increased consulting and professional service fees, including $6,000,000 in litigation costs [198]. - Investment and other income, net decreased by 18% to $5,333,000 from $6,474,000, mainly due to lower market interest rates [199]. - Income tax expense increased by 55% to $43,733,000 from $28,136,000, attributed to higher income before tax [201]. - Net cash provided by operating activities increased by $131,932,000 to $432,529,000 for the nine months ended September 30, 2025 [212]. - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $702,000,000, sufficient to fund operations for at least the next 12 months [210]. Debt and Financing - As of September 30, 2025, the conditional conversion feature of the 2028 Convertible Notes was triggered, classifying them as current portion of long-term debt [219]. - The initial conversion rate for the 2028 Convertible Notes is 17.8517 shares per $1,000 principal amount, equivalent to a conversion price of approximately $56.02 per share [220]. - The cap price of the Capped Call Transactions is initially $75.4075 per share, representing a 75% premium above the last reported sale price of $43.09 per share on August 15, 2022 [221]. - The company paid approximately $69.1 million for the Capped Calls, recorded as a reduction to additional paid-in capital [222]. - The company completed the sale of $805.0 million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027, with net proceeds of approximately $784.9 million after fees [223]. - The initial conversion rate for the 2027 Convertible Notes is 12.9576 shares per $1,000 principal amount, equivalent to a conversion price of approximately $77.17 per share [226]. - The 2022 Credit Agreement provides for a $575 million revolving credit facility and a $250 million term loan facility, maturing on November 30, 2026 [227]. - The Term Facility requires quarterly repayments of 2.50%, 5.00%, 7.50%, and 10.00% of the initial principal amount in the first four years, respectively [228]. - As of September 30, 2025, the revolving credit facility was undrawn [230]. - The company does not believe that an immediate change of 10% in interest rates would materially impact its results of operations [237].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ……………..to …………….. Commission File Number: 814-00061 CAPITAL SOUTHWEST CORPORATION (Exact name of registrant as specified in its charter) Texas 75-1072796 ...